Healthcare / BiotechnologyLSE
$550.00
+0.00 (+0.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-7.7M · quality 75.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
29/100
D
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$85M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-46.8%
↓Gross Margin
67.5%
↑Debt/Equity
0.58
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2021–2024 · 3 años de histórico normalizado
Revenue CAGR
+40.3%
FCF CAGR
—
FCF margin
-1319.9%
FCF / Net income
1.00x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $933000.0 · net income $-12.3M · FCF $-12.3M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $933000.00 | $933000.00 | $506000.00 | $268000.00 | $338000.00 |
| Net Income | $-12.3M | $-12.3M | $-7.7M | $-5.2M | $-3.2M |
| EBITDA | $-11.0M | $-11.0M | $-7.3M | $-5.4M | $-3.2M |
| EPS | -0.94 | -0.94 | -0.62 | -0.42 | -0.26 |
| Gross Margin | 67.5% | 67.5% | 67.2% | 89.2% | 79.6% |
| Operating Margin | -1371.2% | -1371.2% | -1613.8% | -2115.3% | -943.2% |
| Net Margin | -1321.9% | -1321.9% | -1514.8% | -1921.6% | -957.1% |
| Balance Sheet | |||||
| Debt/Equity | 0.58 | 0.58 | -21.25 | 0.47 | 0.15 |
| Current Ratio | 7.31 | 7.31 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-12.3M | $-12.3M | $-7.7M | $-6.6M | $-4.3M |
| Returns | |||||
| ROE | -46.8% | -46.8% | 1557.9% | -72.3% | -27.7% |
| Valuation | |||||
| P/B | 273.47 | 273.47 | — | 1219.64 | 616.14 |
| Growth & Yield | |||||
| Revenue Growth | 84.4% | 84.4% | 88.8% | -20.7% | — |
| EPS Growth | -51.6% | -51.6% | -47.6% | -61.5% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-50.5%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.62 → -0.94
Residual
-50.5%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.